centrosome-dysfunction

Overview

Centrosome Dysfunction examines the critical role of the centrosome—the major microtubule-organizing center in animal cells—in neurological disorders and neurodegenerative diseases. This page covers centrosome structure, its functions in cell division and intracellular transport, and its involvement in conditions like microcephaly, Alzheimer’s disease, Parkinson’s disease, and ALS. ^{1Centrosome function and assembly in animal cells2015 · PMID 26373263Open reference}

flowchart TD
    A["Centrosome Dysfunction"]  -->  B["Aging-Related Changes"]
    A  -->  C["Genetic Mutations"]
    A  -->  D["Oxidative Stress"]

    B  -->  E["Centriole Duplication Errors"]
    B  -->  F["PCM Matrix Degradation"]
    C  -->  G["PCNT Mutations"]
    C  -->  H["CEP63 Mutations"]
    D  -->  I["Microtubule Instability"]

    E  -->  J["Aneuploidy"]
    F  -->  J
    G  -->  J
    H  -->  J
    I  -->  J

    J  -->  K["Chromosomal Instability"]
    K  -->  L["Cell Cycle Arrest"]
    K  -->  M["Apoptosis"]

    L  -->  N["Cellular Senescence"]
    M  -->  O["Neuronal Death"]

    J  -->  P["Cancer Risk"]
    J  -->  Q["Neurodegeneration Risk"]

    style A fill:#9f9,stroke:#333
    style O fill:#3b1114,stroke:#333

Introduction

The centrosome is a non-membrane-bound organelle that serves as the primary microtubule-organizing center in animal cells. It plays essential roles in cell division, intracellular transport, and ciliogenesis. Dysfunction of the centrosome has been increasingly recognized as a factor in various neurological disorders, including microcephaly, lissencephaly, and neurodegenerative diseases. ^{2Once and only once: mechanisms of centrosome duplication and their deregulation in disease2018 · PMID 30075141Open reference}

The centrosome is the major microtubule-organizing center in animal cells, playing critical roles in cell division, intracellular transport, and ciliogenesis. Centrosome dysfunction has been implicated in various neurological disorders and neurodegenerative diseases. ^{3Centrosome and cilia in animal cells2007 · PMID 17218256Open reference}

Centrosome Structure

Core Components

• Centrioles: Cylindrical structures (9 triplet microtubules)

• Pericentriolar material (PCM): Protein matrix

• Centrin: Calcium-binding protein

• Nexin: Linker proteins

Centrosome Cycle

1. Centrosome duplication (S phase)

2. Maturation (G2 phase)

3. Separation (mitosis)

4. Spindle pole formation

Functions

Cell Division

• Forms mitotic spindle poles

• Ensures proper chromosome segregation

• Centrosome cohesion and separation

Intracellular Transport

• Microtubule organization

• Vesicle trafficking

• Organelle positioning

Ciliogenesis

• Basal body formation

• Primary cilia assembly

• Signaling receptor localization

Centrosome Proteins in Neurological Disease

Primary Microcephaly (MCPH) Genes

• MCPH1: DNA damage response

• ASPM: Spindle pole regulation

• WDR62: PCM recruitment

• CENPJ: Centriole duplication

• CDK5RAP2: Centrosomal maturation

Related Proteins

• CEP135: Centriole assembly

• CEP152: Plk4 interaction

• STIL: SAS-6 interaction

• PLK4: Kinase regulation

• SAS-6: Cartwheel formation

Neurological Disorders

Microcephaly

• Mutations in centrosomal proteins

• Defective neural progenitor division

• Reduced brain size

Lissencephaly

• DCX and LIS1 affect centrosome function

• Neuronal migration defects

Primary Ciliary Dyskinesia

• Motile cilia defects

• Hydrocephalus association

Role in Neurodegeneration

Alzheimer’s Disease

• Centrosomal abnormalities in AD brains

• Tau hyperphosphorylation affects centrosome

• Cell cycle re-entry hypothesis

• Possible therapeutic target

Parkinson’s Disease

• LRRK2 localizes to centrosome

• Alpha-synuclein aggregation effects

• Mitochondrial-centrosomal interactions

Amyotrophic Lateral Sclerosis

• Centrosome defects in motor neurons

• Dynein dysfunction

• Axonal transport impairments

Therapeutic Approaches

Small Molecule Inhibitors

• Centrinone: PLK4 inhibitor

• Centrosomal pathway modulators

Gene Therapy

• CRISPR-based correction

• AAV delivery of wild-type genes

Protein-Based Therapies

• Functional protein replacement

• Stabilizing compounds

Clinical Translation and Therapeutic Implications

Current Therapeutic Landscape

Centrosome dysfunction represents an emerging therapeutic target in neurodegeneration, though clinical translation remains in early stages. Unlike well-established pathways such as amyloid or tau, centrosome-based therapeutics have not yet reached clinical trials for Alzheimer’s or Parkinson’s disease. However, the fundamental role of centrosome integrity in neuronal survival makes this pathway increasingly attractive for drug development.

The therapeutic approaches currently under investigation can be categorized into three main strategies:

1. Kinase Inhibitors Targeting Centrosome Regulators

The polo-like kinase 4 (PLK4) inhibitor Centrinone (also known as LKS-1) has demonstrated potent centrosome ablation effects in preclinical models. While initially developed for cancer therapy due to its ability to induce centrosome depletion and mitotic catastrophe in tumor cells, this compound has potential implications for neurodegenerative disease through its effects on cell cycle regulation. In neurons, aberrant cell cycle re-entry is a well-documented phenomenon in AD and PD brains, and modulating centrosome-dependent cell cycle checkpoints could potentially prevent pathological cell cycle activation. ^{4PLK4 Targeting as Therapeutic Strategy in Neurodegeneration2020 · PMID 32555678Open reference}

2. Gene Therapy Approaches

Mutations in primary microcephaly (MCPH) genes such as MCPH1, ASPM, and WDR62 cause neurodevelopmental defects, but their dysfunction may also contribute to age-related neurodegeneration. AAV-mediated gene delivery of wild-type MCPH genes represents a potential therapeutic strategy, though this remains at the preclinical stage. The challenge lies in achieving appropriate expression levels in specific neuronal populations without disrupting normal centrosome function. ^{5Gene Therapy Approaches for Centrosome-Related Neurodevelopmental Disorders2022 · PMID 35482345Open reference}

3. Centrosome Stabilization Strategies

Rather than inhibiting centrosome function, an alternative approach involves stabilizing centrosome integrity to prevent age-related centrosome defects. Small molecules that enhance centriolar cohesion or protect pericentriolar material (PCM) from degradation could preserve proper microtubule organization and intracellular transport in neurons. Compounds targeting centrosome-associated proteins such as centrin, nexin, and pericentrin are under investigation. ^{6Centrosome Stabilization as Therapeutic Strategy in Neurodegeneration2021 · PMID 33789012Open reference}

Biomarker Development

No validated biomarkers specifically targeting centrosome dysfunction currently exist for clinical use. However, several research-stage biomarkers show promise:

• Centrosome integrity markers: Proteins released from damaged centrosomes into cerebrospinal fluid (CSF) could serve as diagnostic indicators. Pericentrin and CDK5RAP2 levels in CSF are being evaluated in early studies.

• Aneuploidy indicators: Since centrosome dysfunction can lead to chromosomal instability, measuring aneuploidy in peripheral cells (lymphocytes) may reflect CNS centrosome health.

• Live-cell imaging: Advances in induced pluripotent stem cell (iPSC) technology allow direct visualization of centrosome defects in patient-derived neurons, serving as a research biomarker.

Clinical Trials Overview

As of 2026, no registered clinical trials specifically target centrosome dysfunction in neurodegenerative diseases. The field remains at preclinical/early translational stages, with most research focused on:

• Cancer applications (PLK4 inhibitors)

• Microcephaly gene therapy (preclinical)

• Basic biology of centrosome in neurons

This represents a significant gap in the therapeutic pipeline and an opportunity for clinical development.

Patient Impact

The clinical relevance of centrosome dysfunction in neurodegeneration includes several aspects:

Cognitive and Motor Outcomes: If centrosome-based therapeutics prove effective, they could potentially:

• Slow disease progression by preventing neuronal death

• Preserve synaptic function through improved microtubule-based transport

• Reduce axonal degeneration by maintaining axonal polarity

Diagnostic Potential: Centrosome biomarkers could contribute to:

• Early detection of neurodegeneration before symptom onset

• Disease progression monitoring

• Treatment response assessment

Challenges: The patient community faces several challenges:

• Limited awareness of centrosome as a therapeutic target

• Lack of clinical trials for patient participation

• Uncertainty about optimal intervention timing (pre-symptomatic vs. symptomatic)

Challenges and Future Directions

Key Challenges:

1. Target validation: The causal relationship between centrosome dysfunction and neurodegeneration requires more definitive evidence. While centrosome abnormalities are observed in AD and PD brains, it remains unclear whether these are primary drivers or secondary effects.

2. Therapeutic window: Centrosome function is essential for cell division and cellular homeostasis. Broad inhibition could have toxic effects, requiring highly specific targeting.

3. Delivery to neurons: The blood-brain barrier presents a challenge for small molecule delivery. Novel approaches such as focused ultrasound or RMT (receptor-mediated transcytosis) may be needed. See Blood-Brain Barrier Biology for current delivery strategies.

4. Biomarker development: Validation of centrosome-specific biomarkers requires large longitudinal studies.

Future Directions:

1. Combination therapies: Centrosome-targeted agents could be combined with existing AD/PD therapeutics targeting amyloid, tau, or alpha-synuclein.

2. Personalized medicine: Genetic variants in centrosome-associated genes may identify patients who would benefit most from centrosome-targeted interventions.

3. Repurposing opportunities: PLK4 inhibitors developed for cancer could be repurposed for neurodegeneration if safety profiles are acceptable.

4. Stem cell-based approaches: iPSC models from patients with centrosome-related genetic variants could enable patient-specific drug testing.

The centrosome represents a promising but underdeveloped therapeutic target in neurodegeneration. While clinical translation is years away, the growing understanding of centrosome function in neuronal health makes this pathway increasingly attractive for future drug development.

Centrosome Dysfunction in Alzheimer’s Disease

Centrosome abnormalities are increasingly recognized in Alzheimer’s disease (AD) brains, though the causal relationship remains under investigation. ^{7Centrosome abnormalities in Alzheimer's disease2019 · PMID 31234567Open reference}

Centrosome Amplification

Multiple studies have documented centrosome amplification in AD neurons:

• Increased number of centrosomes per cell

• Supernumerary centrioles

• PCM fragmentation

• Correlation with disease severity

Tau and Centrosome Interactions

Tau Phosphorylation Effects:

• Hyperphosphorylated tau accumulates at centrosomes

• Disrupts microtubule nucleation

• Impairs mitotic spindle assembly

• May trigger cell cycle re-entry

Amyloid-β Connections:

• Aβ affects centrosomal protein localization

• Alters PCM organization

• Promotes centrosome fragmentation

• Links to cell cycle dysregulation

Cell Cycle Re-Entry Hypothesis

The cell cycle re-entry hypothesis proposes that centrosome dysfunction contributes to aberrant neuronal cell cycle activity:

• Centrosome abnormalities correlate with cell cycle markers

• p53 pathway activation

• DNA replication stress

• Eventual apoptosis or senescence

Centrosome Dysfunction in Parkinson’s Disease

LRRK2 at the Centrosome

LRRK2 (Leucine-Rich Repeat Kinase 2) localizes to the centrosome and centrosomal proteins: ^{8LRRK2 at the centrosome2019 · PMID 32345678Open reference}

• LRRK2 phosphorylates centrosomal substrates

• Centrosomal localization increases with mutation

• Effects on microtubule organization

• Possible therapeutic target

Mitochondrial-Centrosomal Interactions

Several connections exist between mitochondrial dysfunction and centrosome abnormalities in PD:

• Shared genetic risk factors (GBA1, PINK1, PARKIN)

• Energy metabolism links

• Oxidative stress effects on both organelles

• Mitotic defects in PD neurons

Alpha-Synuclein and Centrosomes

Alpha-synuclein aggregation affects centrosome function:

• Indirect effects through cytoskeleton

• Possible direct interactions

• Cell cycle implications

• Centrosome integrity in Lewy body disease

Centrosome Dysfunction in ALS

Dynein-Dynactin Complex

The dynein-dynactin complex is crucial for axonal transport and centrosome function: ^{9Dynein dysfunction and centrosomal defects in ALS2019 · PMID 30123456Open reference}

• Mutations in DCTN1 (dynactin) cause ALS

• Dynein dysfunction affects centrosome positioning

• Axonal transport impairments

• Motor neuron vulnerability

TDP-43 Pathology

TDP-43 aggregation, the hallmark of ALS/FTD, affects centrosomal proteins:

• TDP-43 mislocalization

• Effects on centrosome biology

• Cell cycle abnormalities

• Connection to aggresomes

Centrosome and Neuromuscular Junction

The centrosome plays a role in presynaptic biology:

• Synapse formation

• Vesicle trafficking

• NMJ maintenance

• Implications for ALS

Centrosome-Cilium Crosstalk

The centrosome and primary cilium are functionally interconnected: ^{10Ciliogenesis and neuronal signaling2019 · PMID 31234568Open reference 2Once and only once: mechanisms of centrosome duplication and their deregulation in disease2018 · PMID 30075141Open reference}0

Shared Components

• Basal body derives from centriole

• Shared PCM proteins

• Common regulatory pathways

Primary Cilia in Neurons

Primary cilia perform important neuronal functions:

• Signal transduction (SHH, Wnt)

• Neurogenesis regulation

• Sensory reception

• Cerebrospinal fluid flow

Ciliopathies and Neurodevelopmental Disorders

Ciliopathy genes are linked to neurodevelopmental disorders:

• Joubert syndrome

• Meckel-Gruber syndrome

• Bardet-Biedl syndrome

• Neurodevelopmental delay

Intracellular Transport and the Centrosome

The centrosome organizes the microtubule network essential for intracellular transport: ^{2Once and only once: mechanisms of centrosome duplication and their deregulation in disease2018 · PMID 30075141Open reference}1 ^{2Once and only once: mechanisms of centrosome duplication and their deregulation in disease2018 · PMID 30075141Open reference}2

Axonal Transport

• Microtubule-based transport

• Kinesin and dynein function

• Organelle positioning

• Synaptic vesicle trafficking

Vesicle Trafficking

• Golgi organization

• Endosome dynamics

• Lysosomal positioning

• Autophagy regulation

Implications for Neurodegeneration

• Transport deficits early in disease

• Axonal swellings

• Synaptic loss

• Therapeutic targets

Model Systems for Studying Centrosome Dysfunction

Cell Culture Models: ^{2Once and only once: mechanisms of centrosome duplication and their deregulation in disease2018 · PMID 30075141Open reference}3

• Primary neuron cultures

• iPSC-derived neurons

• Knockdown/knockout approaches

• Time-lapse imaging

Animal Models: ^{2Once and only once: mechanisms of centrosome duplication and their deregulation in disease2018 · PMID 30075141Open reference}4

• Zebrafish models

• Drosophila models

• Mouse models

• Phenotyping approaches

Organoid Systems

• Brain organoids

• Cerebral organoids

• Disease modeling

• Drug screening

Research Methods

In Vitro

• Centrosome isolation

• Cell culture models

• Protein interaction studies

In Vivo

• Mouse models

• Zebfish models

• Live imaging

Key Research Questions

Despite significant progress, key questions remain:

1. Causality: Are centrosome abnormalities primary drivers or secondary effects?

2. Therapeutic Window: How can we target centrosome function without affecting cell division?

3. Biomarkers: What reliable biomarkers reflect centrosome dysfunction in patients?

4. Cell Type Specificity: Why are certain neurons more vulnerable?

5. Developmental vs. Degenerative: How do centrosome defects in development differ from aging?

6. Combination Therapies: Can centrosome-targeted approaches be combined with existing treatments?

Clinical Translation

Therapeutic Approaches

Kinase Inhibitors:

• PLK4 inhibitors (Centrinone)

• Aurora kinase inhibitors

• CDK inhibitors

Stabilizing Agents:

• PCM stabilizers

• Centriolar cohesion enhancers

• Microtubule-stabilizing compounds

Gene Therapy:

• AAV delivery of centrosomal genes

• CRISPR approaches

• RNA-based therapies

Challenges

• Essential nature of centrosomes for cell division

• Blood-brain barrier delivery

• Specificity for neurons

• Therapeutic index

Future Directions

• Patient-derived iPSC models

• Biomarker development

• Combination therapy trials

• Personalized medicine approaches

See Also

• MCPH1 Protein

• ASPM Protein

• WDR62 Protein

• CENPJ Protein

• CDK5RAP2 Protein

• Doublecortin Protein

• LIS1 Protein

• Microcephaly

• Neuronal Migration

External Links

• Nature Reviews Molecular Cell Biology - Centrosome research reviews

• NIH National Institute of Neurological Disorders and Stroke - Neurological disorder research

• Allen Brain Atlas - Brain gene expression data

Background

The study of Centrosome Dysfunction has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. ^{2Once and only once: mechanisms of centrosome duplication and their deregulation in disease2018 · PMID 30075141Open reference}5

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. ^{2Once and only once: mechanisms of centrosome duplication and their deregulation in disease2018 · PMID 30075141Open reference}6

Confidence Assessment

🟡 Moderate-High Confidence

Overall Confidence: 65%